Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14115640 | 0.85 | HSP90AB1 (0.56) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL4113212 | 0.84 | CYP4F2 (0.76) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL7272639 | 0.83 | L3MBTL1 (0.48) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL9647592 | 0.83 | CYP4F2 (0.59) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL2662135 | 0.81 | CYP4F2 (0.58) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL17653825 | 0.81 | CYP4F2 (0.53) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL8787287 | 0.80 | CYP4F2 (0.56) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL8787884 | 0.80 | CYP4F2 (0.56) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL7399916 | 0.80 | ALDH1A1 (0.52) | CYP4F2CYP4A11ALDH1A1GAAGFER | |
| SCHEMBL4971051 | 0.79 | CYP4F2 (0.54) | CYP4F2CYP4A11ALDH1A1GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | UPPTHERA INC. (KR) | 2023-03-16 | — | — | US | disclosed |
| WO-2021201577-A1 | HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2021-10-07 | — | — | WO | disclosed |
| US-6992193-B2 | Sulfonylamino phenylacetamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-01-31 | — | — | US | disclosed |
| WO-2005004796-A2 | SULFONYLAMINO PHENYLACETAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040254156-A1 | Sulfonylamino phenylacetamide derivatives and methods of their use | CALIXA THERAPEUTICS, INC. | 2004-12-16 | — | — | US | disclosed |
| EP-0874826-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997024331-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254156-A1 | Sulfonylamino phenylacetamide derivatives and methods of their use | CYP2E1, CYP2D6, CYP3A43 | CYP4F2 44/4885CYP4A11 49/4885ALDH1A1 94/4885 |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | HMGCR, HMGB2, LDLR | CYP4F2 378/4885CYP4A11 118/4885ALDH1A1 1022/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | CYP4F2 378/4885CYP4A11 118/4885ALDH1A1 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.